natgillin/translations-raw huggingface dataset:
other non-immune diseases/conditions with similar clinical signs included in the differential diagnosis (such as BVD, nitrofuran treatment) should be excluded. 
izključiti je treba druge neimunske bolezni/stanja s podobnimi kliničnimi znaki, ki so vključena v diferencialno diagnozo (kot sta bovina virusna diareja (BVD), zdravljenje z nitrofuranom).
The frequency of this condition had been dramatically exacerbated by PregSure BVD vaccination in the 2000's leading to the characterisation of a strong association between the occurrence of BNP and the use of Pregsure BVD; however the frequency of BNP disease caused by PregSure BVD vaccination has not been solidly determined, varying from 5% to 0.004% according to the source; the CVMP approximated this frequency to be around 0.01% during the Article 78 procedure. 
Pogostnost tega stanja je močno povečalo cepljenje s cepivom PregSure BVD v prvem desetletju 21. stoletja, zaradi česar je bila določena močna povezava med pojavom BNP in uporabo cepiva PregSure BVD; pogostnost bolezni BNP, povzročene s cepljenjem s cepivom PregSure BVD, pa ni bila trdno dokazana, saj se je v različnih virih gibala od 5 % do 0,004 %; odbor CVMP je med postopkom v skladu s členom 78 to pogostnost približno ocenil na 0,01 %.
Overall summary of the scientific evaluation of CattleMarker IBR Inactivated (see Annex I) 
Splošni povzetek znanstvenega vrednotenja cepiva CattleMarker IBR Inactivated (glejte Prilogo I)
The CVMP was asked to consider the issues raised by Germany and conclude whether marketing authorisations for CattleMarker IBR Inactivated should be granted. 
Odbor CVMP je bil naprošen, da preuči vprašanja, ki jih je izpostavila Nemčija, in ugotovi, ali je treba izdati dovoljenja za promet s cepivom CattleMarker IBR Inactivated.
Onset of protection for female cattle is 2 weeks or 19 days prior to breeding or insemination and duration is 12 months post primary vaccination. 
Pri govedu ženskega spola se zaščita razvije dva tedna ali 19 dni pred parjenjem ali osemenitvijo in traja 12 mesecev po osnovnem cepljenju.
− Prior to launch of the vaccine on the market and annually thereafter, provide specific training to the bovine sales and technical teams on the CattleMarker IBR Inactivated product safety profile, BNP and pharmacovigilance obligations. 
− pred dajanjem cepiva na trg in nato enkrat letno zagotovi posebno usposabljanje za skupine, ki se ukvarjajo s prodajo govedine in tehnične skupine, glede varnostnega profila cepiva CattleMarker IBR Inactivated, BNP in obveznosti glede farmakovigilance;
Prior to placing CattleMarker IBR Inactivated on the EU market the results should be submitted to the national competent authorities to be assessed by the authorities to their satisfaction. 
Pred dajanjem cepiva CattleMarker IBR Inactivated na trg EU je treba rezultate predložiti pristojnim nacionalnim organom, da jih ocenijo kot zadovoljive;
Annex IV Conditions of the marketing authorisations 
Priloga IV Pogoji dovoljenj za promet z zdravilom
A filtration step using three filtration membranes has been integrated into the production process for clarification of the antigen preparations. 
Zaradi pojasnitve antigenskih pripravkov je bilo v postopek proizvodnje vključeno filtriranje z uporabo treh filtrirnih membran.
Updates to the risk management plan should be proposed as required as soon as any issues arise, otherwise the risk management plan should be reviewed on a yearly basis at least, in conjunction with the PSUR submission. 
V skladu z zahtevami se posodobitve načrta za obvladovanje tveganj predložijo nemudoma ob pojavu morebitnih težav, sicer pa je treba načrt za obvladovanje tveganj pregledati vsaj enkrat letno, in sicer ob predložitvi redno posodobljenih poročil o varnosti zdravila.
Any confirmed BNP calves will also be assessed for MHC-I alloantibodies. 
Vsako tele, pri katerem se potrdi okužba z BNP, se prav tako oceni glede aloprotiteles MHC-I.
An association between BNP and alloimune reaction to Antigens Not related to the Active Substance (ANAS) (e.g. bovine kidney cell line derived antigens and all antigenic substances remaining from the manufacturing process) is widely accepted. 
Povezava med BNP in aloimunsko reakcijo na antigene, ki niso povezani z zdravilno učinkovino (ANAS) (npr. antigeni, pridobljeni iz ledvične celične linije, pridobljene iz goveda, in vse antigenske snovi, ki so ostale po postopku izdelave), je splošno sprejeta.
In 2010, due to these concerns, a procedure under Article 78 of Directive 2001/82/EC was initiated in which the CVMP concluded that although the aetiology of BNP had yet to be determined there was evidence to suggest that PregSure BVD may be associated with BNP and that the benefit-risk balance for the product was unfavourable. 
V zvezi s ti zadržki je bil leta 2010 sprožen postopek v skladu s členom 78 Direktive 2001/82/ES, v katerem je odbor CVMP ugotovil, da so kljub še neugotovljeni etiologiji BNP obstajali dokazi, da je cepivo PregSure BVD lahko povezano z BNP in da je razmerje med tveganji in koristmi cepiva neugodno.
Nonetheless in the assessment in the frame of this procedure under Article 78 of Directive 2001/82/EC the frequency of the BNP caused by PregSure BVD was approximated to be around 0.01% by the CVMP. 
Ne glede na to je odbor CVMP v okviru tega postopka v skladu s členom 78 Direktive 2001/82/ES ocenil, da je pogostnost BNP, ki jo povzroči cepivo PregSure BVD, približno 0,01 %.
BNP is a disease which can be fatal in neonatal calves and which has been experimentally reproduced by the intake of colostrum from dams which have alloantibodies. 
BNP je bolezen, ki je lahko smrtna za novorojena teleta in ki so jo poskusno ponovili z vnosom kolostruma iz samic z aloprotitelesi.
If dead, bone marrow histopathology shows trilineage hypoplasia. 
2. če je žival mrtva, se s histopatologijo kostnega mozga dokaže trilinijska hipoplazija;
These results show that the overall protein content per ml is higher in BVDV-1 antigen batches than in BoHV1 antigen batches. 
Rezultati kažejo, da je celokupna vsebnost beljakovin na mililiter v serijah antigena BVDV-1 višja kot v serijah antigena BoHV-1.
the calf should have a blood pancytopenia consecutive to bone marrow aplasia, 3.) 
tele mora imeti pancitopenijo, ki je posledica aplazije kostnega mozga; 3.)
• The marketing authorisation holder shall include a new specification in the finished product of a maximum total protein content. 
• imetnik dovoljenja za promet z zdravilom vključi v končno zdravilo novo specifikacijo najvišje skupne vsebnosti beljakovin.
Scientific conclusions and grounds for the granting of the marketing authorisations 
Priloga II Znanstveni zaključki in podlaga za izdajo dovoljenj za promet
− In addition to the usual pharmacovigilance system for the monitoring of animals vaccinated with CattleMarker IBR Inactivated, to conduct thorough investigations for any unexplained mortality in the offspring of vaccinated animals following documented use of CattleMarker IBR Inactivated. 
− poleg običajnega sistema farmakovigilance za spremljanje živali, cepljenih s cepivom CattleMarker IBR Inactivated, izvaja natančne raziskave vsake nepojasnjene smrti mladičev cepljenih živali po zabeleženi uporabi cepiva CattleMarker IBR Inactivated.
− Send out a letter to all customers receiving the CattleMarker IBR Inactivated for the first time with additional information to raise awareness for possible BNP cases. 
− vsem kupcem, ki prvič kupijo cepivo CattleMarker IBR Inactivated, pošlje dopis z dodatnimi informacijami, da poveča zavedanje o možnih primerih BNP;
− The marketing authorisation holder should consider the development a method for assaying the protein content in the finished product. 
− imetnik dovoljenja za promet z zdravilom preuči razvoj metode za preizkušanje vsebnosti beljakovin v končnem cepivu;
The potential risk deriving from the intended use of CattleMarker IBR Inactivated to trigger BNP is associated with the composition and manufacture of the vaccine and more specifically with the amount of Antigens Not related to the Active Substance (ANAS) and is also linked to the use of the vaccine in female cattle subject to repeated vaccinations. 
Možno tveganje pojava BNP zaradi predvidene uporabe cepiva CattleMarker IBR Inactivated je povezano s sestavo in izdelavo cepiva ter zlasti s količino antigenov, ki niso povezani z zdravilno učinkovino (ANAS), in z uporabo cepiva pri govedu ženskega spola, pri katerih se izvajajo ponavljajoča cepljenja.
CattleMarker IBR Inactivated fulfils the criteria for an effective IBR marker vaccine and provides the full therapeutic benefit. 
Cepivo CattleMarker IBR Inactivated izpolnjuje merila za učinkovito markirano cepivo proti infekcioznemu bovinemu rinotraheitisu in zagotavlja popolno terapevtsko korist.
− Utilise the existing colostrum practices in case of BNP cases and develop further mitigation measure for colostrum. 
− ob pojavu okužb z BNP uporabi obstoječe prakse za kolostrum in pripravi nadaljnji ukrep za zmanjšanje tveganja pri kolostrumu.
In the past initially epidemiological information and then rapidly increasing pharmacovigilance data documented an increase of the frequency of this alloimmune reaction between the dam and the foetus and finally a close relationship between the occurrences of BNP and the repeated vaccination of dams with PregSure BVD was established. 
V preteklosti so beležili povečanje pogostnosti te aloimunske reakcije med materjo in plodom, najprej na podlagi epidemioloških informacij in pozneje hitro naraščajočih farmakovigilančnih podatkov, kar je vodilo do ugotovitve o tesni povezavi med pojavi BNP in ponavljajočim cepljenjem samic s cepivom PregSure BVD.
Applicant/marketing authorisation holder 
Vlagatelj/imetnik dovoljenja za promet z zdravilom
Several live and inactivated IBR marker vaccines are authorised and successfully used throughout the EU. 
V EU je odobrenih več živih in inaktiviranih markiranih cepiv proti infekcioznemu bovinemu rinotraheitisu, ki se uspešno uporabljajo.
The abovementioned study results should be provided to the relevant national competent authorities for assessment prior to placing CattleMarker IBR Inactivated on the EU market and within 24 months of the Commission Decision. 
Rezultate zgoraj navedene študije je treba pred dajanjem cepiva CattleMarker IBR Inactivated na trg EU predložiti ustreznim pristojnim nacionalnim organom v oceno in v 24 mesecih po izdaji sklepa Komisije.
Furthermore, the MAH has made post authorisation commitments to set a maximum level of total proteins for batch release and to perform two additional studies in order to investigate possible interactions of vaccinations with CattleMarker IBR Inactivated in animals previously vaccinated with PregSure BVD or other vaccines. 
Poleg tega se je imetnik dovoljenja za promet z zdravilom po pridobitvi dovoljenja za promet zavezal, da bo določil najvišjo vsebnost skupnih beljakovin za sproščanje serij in da bo opravil dve dodatni študiji, s katerima bo raziskal možno medsebojno delovanje cepljenja s cepivom CattleMarker IBR Inactivated pri živalih, ki so bile že cepljene s cepivom PregSure BVD ali drugimi cepivi.
The MAH proposed a post-marketing pharmacovigilance surveillance program utilising its usual pharmacovigilance system for the monitoring of animals vaccinated with CattleMarker IBR Inactivated. 
Imetnik dovoljenja za promet z zdravilom je predlagal program za nadzor farmakovigilance v obdobju trženja z uporabo običajnega sistema farmakovigilance za spremljanje živali, cepljenih s cepivom CattleMarker IBR Inactivated.
The potential risk of recurrence of BNP linked to the use of this vaccine in pregnant cows has been addressed by the MAH; however Germany considered that the proposed handling of the risks was inadequate and that a large scale post authorisation study should be initiated by the MAH. 
Imetnik dovoljenja za promet z zdravilom je obravnaval možno tveganje za ponovitev pancitopenije novorojenega goveda v povezavi z uporabo tega cepiva pri brejih kravah, vendar pa je bilo po mnenju Nemčije predlagano obvladovanje tveganja neustrezno in bi moral imetnik dovoljenja za promet z zdravilom začeti obsežno študijo o varnosti zdravila po pridobitvi dovoljenja za promet.
• The marketing authorisation holder shall conduct a controlled laboratory study to confirm that hyperimmunisation of cattle with CattleMarker IBR Inactivated does not induce a significant alloantibody response to MHC-I and MDBK cells and also to assess if vaccination with other cattle vaccines produced on bovine cell lines and with high amount of ANAS followed by booster with CattleMarker IBR Inactivated leads to a significant increase in alloantibody titres against MHC-I and MDBK cells. 
• imetnik dovoljenja za promet z zdravilom bo opravil kontrolirano laboratorijsko študijo, s katero bo potrdil, da hiperimunizacija goveda s cepivom CattleMarker IBR Inactivated ne sproži večjega odziva aloprotiteles na celice MHC-I in MDBK, in tudi ocenil, ali cepljenje z drugimi cepivi za govedo, proizvedenimi na celičnih linijah goveda, in z velikimi količinami ANAS, ki se pojavijo po obnovitvenem cepljenju s cepivom CattleMarker IBR Inactivated, povzroči znatno povečanje titrov aloprotiteles proti celicam MHC-I in MDBK.
If alive, profound thrombocytopenia (with or without neutropenia, lymphopenia and nonregenerative anaemia). 
3. če je žival živa, se ugotavlja izražena trombocitopenija (z nevtropenijo, limfopenijo in neregenerativno anemijo ali brez njih);
• to reduce the clinical signs (pyrexia and duration of dyspnoea) of infectious bovine rhinotracheitis (IBR) and virus shedding caused by BoHV-1 infection; 
• zmanjšanja kliničnih znakov (pireksije in trajanja dispneje) infekcioznega bovinega rinotraheitisa (IBR) in skrajšanja trajanja izločanja virusa, ki ga povzroča okužba z virusom BoHV-1;
CattleMarker IBR Inactivated emulsion for injection for cattle (thereafter called CattleMarker IBR Inactivated) is an inactivated infectious bovine rhinotracheitis (IBR) vaccine which contains glycoprotein E (gE) negative bovine herpes virus 1 (BoHV-1), strain Difivac. 
Emulzija za injiciranje za govedo CattleMarker IBR Inactivated (v nadaljnjem besedilu: CattleMarker IBR Inactivated) je inaktivirano cepivo proti infekcioznemu bovinemu rinotraheitisu (IBR), ki vsebuje glikoprotein E (gE)-negativen goveji herpesvirus tipa 1 (BoHV-1), sev Difivac.
The product is indicated for active immunisation of seronegative cattle from 2 weeks of age to reduce the clinical signs (pyrexia and depression) of IBR and the duration of virus shedding caused by BoHV-1 infection. 
Cepivo je indicirano za aktivno imunizacijo seronegativnega goveda, starega dva tedna ali več, za zmanjšanje kliničnih znakov (pireksije in depresije) infekcioznega bovinega rinotraheitisa in skrajšanje trajanja izločanja virusa, ki ga povzroča okužba z virusom BoHV-1.
Onset and duration of protection for the seronegative cattle form 2 weeks of age is 2 weeks and 6 months respectively after completion of the primary vaccination 
Pri seronegativnem govedu, starem dva tedna ali več, se zaščita razvije dva tedna po zaključku osnovnega cepljenja in traja šest mesecev po osnovnem cepljenju.
Later the marketing authorisations for PregSure BVD were withdrawn by the MAH Pfizer (now Zoetis) from all EU and in 2011 even from non-EU countries after reports about BNP cases in PregSure BVD-vaccinated herds in New Zealand became public. 
Po objavi poročil o primerih BNP v čredah živali, cepljenih s cepivom PregSure BVD na Novi Zelandiji, je imetnik dovoljenja za promet z zdravilom, družba Pfizer (zdaj Zoetis), umaknil dovoljenja za promet s cepivom PregSure BVD iz vseh držav EU in leta 2011 tudi iz držav, ki niso članice EU.
During the MRP Germany raised a concern about the immunological safety of CattleMarker IBR Inactivated, as the composition of this product is similar to PregSure BVD, a vaccine which has been shown to induce a long-lasting allogeneic antibody response which has been associated with Bovine Neonatal Pancytopenia (BNP), a neonatal alloimmune disease, in the progeny of vaccinated dams. 
Nemčija je med postopkom z medsebojnim priznavanjem izrazila zaskrbljenost glede imunološke varnosti cepiva CattleMarker IBR Inactivated, ker je sestava tega cepiva podobna sestavi cepiva PregSure BVD, za katerega je bilo dokazano, da pri potomcih cepljenih samic sproža dolgotrajen alogenski odziv protiteles, povezan s pancitopenijo novorojenega goveda (BNP), ki je aloimunska bolezen novorojenega goveda.
Finally, by comparison with published data on alloantibody response triggered by other marketed vaccines, the BNP risk for CattleMarker IBR Inactivated appears to be significantly lower than this for PregSure BVD. 
V primerjavi z objavljenimi podatki o odzivu aloprotiteles, ki so ga sprožila druga cepiva na trgu, je tveganje za BNP pri cepljenju s cepivom CattleMarker IBR Inactivated očitno znatno nižje kot pri uporabi cepiva PregSure BVD.
− Utilise the existing GMP product/batch recall procedures. 
− uporabi obstoječe postopke dobre proizvodne prakse (DPP) za odpoklic cepiva/serije.
− Provide a contingency plan in the unlikely circumstance that BNP reports occur that involve CattleMarker IBR Inactivated vaccinated dams. 
− zagotovi načrt ukrepov ob nepredvidljivih dogodkih v malo verjetnih okoliščinah, ko se pojavijo poročila o okužbi z BNP pri samicah, ki so bile cepljene s cepivom CattleMarker IBR Inactivated;
Overall, the benefit-risk balance for CattleMarker IBR Inactivated emulsion for injection is considered positive, subject to the conduct of additional studies and the implementation of further measures specified in a RMP. 
Ocena splošnega razmerja med tveganji in koristmi Razmerje med tveganji in koristmi za cepivo CattleMarker IBR Inactivated emulzija za injiciranje je na splošno pozitivno, pod pogojem, da bodo opravljene dodatne študije in izvedeni nadaljnji ukrepi, opredeljeni v načrtu za obvladovanje tveganj.
• The marketing authorisation holder shall conduct a study to assess the potential booster of CattleMarker IBR Inactivated on any MHC-I or opsonizing alloantibody responses in cattle previously vaccinated using PregSure BVD. 
• imetnik dovoljenja za promet z zdravilom bo opravil študijo, s katero bo ocenil možno obnovitveno cepljenje s cepivom CattleMarker IBR Inactivated na celicah MHC-I ali opsonizacijske odzive aloprotiteles pri govedu, ki je bilo že cepljeno s cepivom PregSure BVD.
gE deleted IBR vaccines such as CattleMarker IBR Inactivated are “DIVA vaccines”, differentiating infected from vaccinated animals. 
Cepiva IBR, ki imajo delecijo specifičnega gena (gE), kot je CattleMarker IBR Inactivated, so „cepiva DIVA“, pri katerih gre za razlikovanje med okuženimi in cepljenimi živalmi.
which will be included in a risk management plan and are deemed adequate and proportionate to the identified risk of development of BNP; the CVMP has recommended the granting of the marketing authorisation for CattleMarker IBR Inactivated emulsion for injection for cattle subject to conditions affecting the marketing authorisations as set out in Annex IV. 
• imetnik dovoljenja za promet z zdravilom je predlagal številne ukrepe za izboljšanje kakovosti ter zmanjševanje tveganja in nadzor, ki bodo vključeni v načrt za obvladovanje tveganj ter se štejejo za ustrezne in sorazmerne ugotovljenim tveganjem za BNP, je odbor CVMP priporočil, da se izda dovoljenje za promet s cepivom CattleMarker IBR Inactivated emulzija za injiciranje za govedo, pod pogoji, ki vplivajo na dovoljenja za promet, kot je določeno v Prilogi IV.
Evaluation of the overall benefit-risk balance 
Ocena razmerja med tveganji in koristmi
Grounds for the granting of the marketing authorisations 
Podlaga za izdajo dovoljenj za promet z zdravilom
In a hyperimmunisation study it has been demonstrated that these remaining ANAS from the manufacturing process of CattleMarker IBR Inactivated did not trigger the production of alloantibodies at a level similar to this of animals hyperimmunised with PregSure BVD. 
S študijo hiperimunizacije je bilo dokazano, da ti ostanki ANAS, ki nastanejo v postopku izdelave cepiva CattleMarker IBR Inactivated, ne povzročijo nastanka enakih količin aloprotiteles kot pri živalih, hiperimuniziranih s cepivom PregSure BVD.
In a hyperimmunisation study, repeated injections of CattleMarker IBR Inactivated did not trigger the production of alloantibodies at a level similar to this of animals hyperimmunised with PregSure BVD. 
Med študijo hiperimunizacije ponovljena injiciranja cepiva CattleMarker IBR Inactivated niso povzročila nastanka podobnih količin aloprotiteles kot pri živalih, hiperimuniziranih s cepivom PregSure BVD.
CattleMarker IBR Inactivated contains the same adjuvant Procision-A as PregSure BVD and the virus production also utilises a bovine-derived kidney cell line (MDBK). 
Cepivo CattleMarker IBR Inactivated vsebuje enak adjuvans Procision-A kot cepivo PregSure BVD, za proizvodnjo virusa pa se prav tako uporablja ledvična celična linija, pridobljena iz goveda (MDBK).
Data has been provided to demonstrate that CattleMarker IBR Inactivated, unlike PregSure BVD, has a reduced amount of immunologically significant amount of ANAS remaining from its manufacturing process on the bovine derived kidney cell line in the final product. 
Na podlagi posredovanih podatkov je bilo dokazano, da ima cepivo CattleMarker IBR Inactivated v nasprotju s cepivom PregSure BVD v končnem zdravilu manj imunološko značilnih ANAS, ki so ostali po postopku izdelave na ledvični celični liniji, pridobljeni iz goveda.
CattleMarker IBR Inactivated has the same highly potent adjuvant, Procision-A, and is grown on the same bovine-derived kidney cell line (MDBK) as PregSure BVD. 
Cepivo CattleMarker IBR Inactivated ima enak zelo močan adjuvans Procision-A in se goji na enaki ledvični celični liniji, pridobljeni iz goveda (MDBK), kot cepivo PregSure BVD.
CattleMarker IBR Inactivated is produced on the same bovine cell line and is adjuvanted with the same highly potent adjuvant, Procision-A, as PregSure BVD. 
Cepivo CattleMarker IBR Inactivated se proizvaja na enaki celični liniji goveda kot cepivo PregSure BVD in dodan mu je enak zelo močan adjuvans, Procision-A.
Romania Zoetis Belgium SA Rue Laid Burniat 1 
Romunija Zoetis Belgium SA Rue Laid Burniat 1
The MAH committed to conducting thorough investigations for any unexplained mortality in the offspring of vaccinated animals following documented use of vaccinesThese measures are proportionate to the BNP risk and include all the current knowledge on BNP gathered from the PregSure BVD incident. 
Zavezal se je, da bo natančno raziskal vsako nepojasnjeno smrt mladičev cepljenih živali po zabeleženi uporabi cepiv.
Belgium Zoetis Belgium SA Rue Laid Burniat 1 
Bolgarija Zoetis Belgium SA Rue Laid Burniat 1
However the manufacturing process of CattleMarker IBR Inactivated leads to an amount of remnant of ANAS (e.g. MDBK cell debris) lower than the one of PregSure BVD. 
Vendar pa je količina ostankov ANAS (npr. ostanki celic MDBK), ki nastanejo pri postopku izdelave cepiva CattleMarker IBR Inactivated, manjša kot pri cepivu PregSure BVD.
Germany Zoetis Belgium SA Rue Laid Burniat 1 
Portugalska Zoetis Belgium SA Rue Laid Burniat 1
• The MAH has provided data demonstrating that the risk that repeated injections with the vaccine 
• imetnik dovoljenja za promet z zdravilom je predložil podatke, ki so dokazovali, da je tveganje, da bi lahko ponavljajoče injiciranje cepiva CattleMarker IBR Inactivated sprožilo pojav BNP, znatno nižje kot pri uporabi cepiva PregSure BVD;
Further information on Tagrisso can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Nadaljnje informacije za zdravilo Tagrisso so na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
This was switched to a full marketing authorisation on 24 April 2017. 
To je bilo 24. aprila 2017 spremenjeno v običajno dovoljenje za promet.
The European Medicines Agency therefore concluded that Tagrisso's benefits are greater than its risks and it can be authorised for use in the EU. 
Evropska agencija za zdravila je zato zaključila, da so koristi zdravila Tagrisso večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.